PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide-Reference-Cited by-同舟云学术

PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide

Published:2017-06 Issue:24 Volume:96 Page:e6817
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Bosso Davide,Pagliuca Martina,Sonpavde Guru,Pond Gregory,Lucarelli Giuseppe,Rossetti Sabrina,Facchini Gaetano,Scagliarini Sarah,Cartenì Giacomo,Daniele Bruno,Morelli Franco,Ferro Matteo,Puglia Livio,Izzo Michela,Montanaro Vittorino,Bellelli Teresa,Vitrone Francesca,De Placido Sabino,Buonerba Carlo,Di Lorenzo Giuseppe

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference14 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. Castration-resistant prostate cancer: current and emerging treatment strategies;Di Lorenzo;Drugs,2010

3. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer;Nelson;J Clin Oncol,2012

4. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

5. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate Cancer Prediction Model Based on Anoikis-Related Genes and Therapeutic Potential of BUB1 in Influencing Epithelial-Mesenchymal Transition;2024-08-26

2. Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients;Scientific Reports;2023-02-15

3. Cancer-Associated Fibroblast Heterogeneity, Activation and Function: Implications for Prostate Cancer;Biomolecules;2022-12-29

4. Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting;Prostate Cancer and Prostatic Diseases;2022-12-14

5. An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression;The Prostate;2019-07-23